You can buy or sell JAZZ and other stocks, options, ETFs, and crypto commission-free!
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. Read More The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Dublin, Ireland.
52 Week High
52 Week Low
Yahoo FinanceMay 8
Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates
Jazz Pharmaceuticals plc JAZZ delivered adjusted earnings of $3.67 per share for the first quarter of 2019, which surpassed the Zacks Consensus Estimate of $3.16. Earnings rose 23% from the year-ago figure driven by higher sales and reduced share count.
The Motley FoolMay 8
Jazz Pharmaceuticals Hits All the Right Notes in Q1
The last time Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced its quarterly results, there were some positives for investors. Revenue increased 17% year over year while earnings were up by 24%. Jazz announced its first-quarter results after the market closed on Tuesday. Did investors receive good news or bad news this time around? Here are the highlights from the company's Q1 update. By the numbers Jazz announced Q1 revenue of $508.2 million, a 14% increase from the $444.6 million reported in the same q...
The Motley FoolMay 8
Jazz Pharmaceuticals (JAZZ) Q1 2019 Earnings Call Transcript
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q1 2019 Earnings Call , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the Jazz Pharmaceuticals plc first-quarter 2019 earnings conference call. [Operator instructions] As a reminder, this conference call is being recorded. I will now turn the call over to Kathee Littrell, head of investor relations at Jazz Pharmaceuticals. Kathee Littrell -- Head of Investor Relations Thank you, Joelle. And ...
$3.16 per share
$3.67 per share